Ascendiant initiated coverage of Cyclo Therapeutics with a Buy rating and $2.60 price target. Cyclo is a drug company specializing in cyclodextrin-based therapies for neuro-degenerative diseases, including Niemann-pick type C and Alzheimer’s disease, the analyst tells investors in a research note. The firm says the patient cultivation of the company’s cyclodextrin platform brings it close to breakthrough therapies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTH: